Titlebook: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag; Proceedings of the N Joel Morganroth,

CIS

Modicum

antenna

New Agents and New Insights for Thrombolytic Therapy in Acute Myocardial Infarction: Focus on Anistr testing. Prourokinase is a fibrin-selective precursor form of urokinase undergoing initial trials both as a single agent and in combinations with urokinase and TPA. These agents expand the spectrum of thrombolytic options and may begin to impact clinical therapy in the near future.

折磨

世俗

canonical

dapper

The Relative Benefit and Risks of Intravenous Streptokinase and Tissue Plasminogen Activator in Acutal infarction, Separate from the generic questions of patient selection criteria has been a sometimes acrimonious commercial issue-tinged debate concerning the relative risks and benefits to be expected following the use of one or the other of these two agents. Arguments center on questions of relat

Immortal

New Agents and New Insights for Thrombolytic Therapy in Acute Myocardial Infarction: Focus on Anistr anisoylated lys-plasminogen and streptokinase which is injected in a dose of 30 U over 2–5 min. Reperfusion rates of 60+10% and patency rates of 70–75% have been observed when it is given in <4 h. Mortality was reduced 48% after anistreplase in one study (AIMS). Intravenous urokinase has yielded re

螢火蟲

鉤針織物